Cisplatin resistance remains a critical obstacle in surgical oncology, with treatment failure exceeding 60% in recurrent solid tumors. The adenovirus type 5 early region 1A (E1A) protein demonstrates remarkable chemosensitization through p53-dependent and p53-... ...

请注册登录后继续浏览